Skip to main content
Caplight Logo









DNA Therapeutics

DNA Therapeutics

Private
FranceHealthcare & Life Scienceshttps://www.dna-therapeutics.com/

Last Round

M&A

Mar 28, 2016

Total Funding Raised

$4M

Company Overview

DNA Therapeutics is a biotechnology company that develops targeted drugs for sensitizing resistant cancer to conventional cancer therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

DNA repair inhibitoroncologybiotechnologydrug discoverycancer therapyradiotherapy sensitizationchemotherapy enhancementclinical-stage biotechprecision medicineDNA damage responsebiopharmadrug candidateclinical trialsnucleic-acid therapeutic

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DNA Therapeutics Comparables

Compare DNA Therapeutics with similar companies based on industry and business-model similarity.

DNA Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Valerio Therapeutics
87%
Artios Pharma
80%
Onco-Innovations
79%

DNA Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AMar 28, 2016
Series AJan 29, 2009
SeedNov 6, 2008

DNA Therapeutics Investors

Notable investors and investment history

DNA Therapeutics investors
InvestorRounds
Inserm TransfertSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2026

    Monthly visitors increased 32% MoM.

  • Apr 17, 2026

    Monthly visitors grew 71% MoM, from 308 to 528.

DNA Therapeutics Filings

Explore SEC and related filing metadata, where available.

DNA Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about DNA Therapeutics's valuation, stock price, and market status.

Is DNA Therapeutics a public or private company?

DNA Therapeutics is a private company.

What is the current stock price of DNA Therapeutics?

DNA Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is DNA Therapeutics worth (valuation)?

Valuation information for DNA Therapeutics is not publicly available.

Can I buy DNA Therapeutics stock?

DNA Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was DNA Therapeutics's last funding round?

DNA Therapeutics's most recent funding round was M&A on March 28, 2016.

Who are the main investors in DNA Therapeutics?

Key investors in DNA Therapeutics include Inserm Transfert.

Will DNA Therapeutics IPO soon?

No public IPO plans have been announced for DNA Therapeutics.

How can I track DNA Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor DNA Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersFrance
Employee Range3
Year Founded2006
Last FundingMar 28, 2016

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?